 |
The goal of our research is to develop novel anticancer drugs that are more effective and have a minimum risk of adverse reactions to patients than the drugs currently available in the clinic. Toward this goal, we have been performing comprehensive gene expression analysis using cDNA microarray in the collaboration with the laboratory of Professor Yusuke Nakamura, at Human Genome Center, Institute of Medical Science, the University of Tokyo.
Recent progress in human genome science and molecular biology rapidly accelerated identification of genes involved in development/progression of various human cancers. Such information has been applied for the development of novel drugs, and led to the success of molecular-targeted drugs that antagonize specific molecules playing critical roles in cancer. Molecular-targeted anticancer drugs such as Herceptine, Glivec, and Iressa are already used in the clinic, and their efficacy has been impressively proven. However, the number of molecular-targeted anticancer drugs is still limited, and a large number of patients are still looking for novel molecular-targeted drugs that can cure their diseases. Therefore, we have been doing our best efforts to develop novel molecular-targeted anticancer drugs that have specific therapeutic effect to cancer cells by focusing on molecules that are expressed abundantly in cancer cells but barely in normal tissues.
Fundamental Research technologies in OTS
- Laser Micro-beam Microdissection (LMM)
- Genome-wide cDNA microarray
- Molecular target genes
Pharmaceutical Research
- Antibodies (for treatment and diagnosis)
- Small-molecular drugs and RNAi medicines
- Peptide vaccines
Pipe line
- Antibody therapy
- Cancer peptide vaccines
- Preclinical study
- Clinical study
|
|
